ISNES, Belgium, Aug. 1, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that its first product the "Total Nu.Q™ Assay" research use only (RUO) kit, is ready and available for purchase through Active Motif, its Global Sales and Distribution Partner (https://www.activemotif.com/catalog/1266/NuQ-total-assay). This kit, based on Volition's proprietary Nucleosomics® technology, is the first in a range of kits due to be released over the coming months.
Founder and Chairman of Active Motif, Joseph M. Fernandez, commented "We are continuously looking for innovative products in the field of epigenetics and believe that Nucleosomics® is a breakthrough technology. These RUO kits will provide researchers throughout the world with a new way to explore epigenetic modifications in circulating cell-free nucleosomes across different diseases from clinical samples. We are delighted that the first kit is now available for sale and continue to work with Volition to develop a broad range of assays focused on important targets for future roll-out. We expect revenue this quarter from the sales of these RUO kits."
The RUO kits are based on the same Nu.Q™ immunoassay technology as Volition's cancer screening panels and may be used to investigate a variety of clinical questions beyond Volition's core focus in cancer biomarkers. The range of the RUO kits will allow researchers to explore patterns of epigenetic modifications in circulating nucleosomes in disease models, pre-clinical testing and clinical trials across a broad spectrum of clinical applications including cancer, inflammatory and infectious diseases and trauma. The RUO kits will offer a complete profiling solution from cell to serum.
Chief Executive Officer of Volition, Cameron Reynolds, commented, "This is a fantastic achievement for both Volition and Active Motif; it was very exciting to see the first pack come off the production line. We expect that the RUO kits will provide an additional revenue stream beyond that from the expected commercialization of our blood-based tests for cancer. If the assays are developed as a companion diagnostic for another company's therapeutic, this could also potentially result in further future revenue through a licensing or similar arrangement."
An interview with Cameron Reynolds and Mark Eccleston, Business Development Director of Volition regarding, the RUO Kits is available to view at https://volitionrx.com/news/video-gallery
About Active Motif
Active Motif is an industry leader in developing and delivering innovative tools to enable epigenetics and gene regulation research for the life science, clinical and pharmaceutical and drug discovery communities. The company has a significant portfolio of assays, genome wide services and validated antibodies for use in ChIP-Seq. Active Motif operates globally through its corporate headquarters in Carlsbad, California, regional headquarters in Belgium, Japan and China, as well as a worldwide network of sales and support offices. Active Motif applies a multi-disciplinary approach to create new and modify existing technologies to meet the current and future needs of life science researchers. To learn more please visit www.activemotif.com.
Volition is a multi-national life sciences company focused on developing simple, easy to use, cost effective blood tests designed to help diagnose a range of cancers. The tests are based on the technology platform of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present.
As cancer screening programs become more widespread, Volition's products aim to help to diagnose a range of cancers quickly, simply, accurately and cost effectively. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life.
Volition intends to expand the application of its technology beyond cancer by exploring other disease applications. The company's research and development activities are currently centered in Belgium, with additional offices in London, Texas and Singapore, as it focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.
For more information about Volition, visit Volition's website https://volitionrx.com/
or connect with us via:
The contents found at Volition's website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference into this document and should not be considered part of this document. The addresses for Volition's website, Twitter, LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only. The contents found at any third party's website address are the sole responsibility of such third party, are not incorporated by reference into this document, such website addresses are to be considered inactive textual references only, and Volition makes no representations or warranties regarding such contents.
Louise Day, Chief Marketing & Communications Officer
+44 (0)7557 774620
Scott Powell, Executive Vice President, Investor Relations
+1 (646) 650 1351
Joseph Green, Edison Advisors
+1 (646) 653 7030
Safe Harbor Statement
Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to the effectiveness of Volition's bodily-fluid-based diagnostic tests as well as Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and/or other disease applications. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties. For instance, if Volition fails to develop and commercialize diagnostic products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products in the clinical IVD market; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic products Volition might develop; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; and other risks identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.
Nucleosomics®, NuQ®, Nu.Q™ and Hypergenomics® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners. Additionally, unless otherwise specified, all references to "$" refer to the legal currency of the United States of America.
SOURCE VolitionRx Ltd